Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES

MLA

Szarek, Michael, et al. “Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.” European Journal of Preventive Cardiology, vol. 31, no. 10, Aug. 2024, pp. e75–78. EBSCOhost, https://doi.org/10.1093/eurjpc/zwae110.

APA

Szarek, M., Reijnders, E., Steg, P. G., Jukema, J. W., Schwertfeger, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., White, H. D., Zeiher, A. M., Cobbaert, C., & Schwartz, G. G. (2024). Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. European Journal of Preventive Cardiology, 31(10), e75–e78. https://doi.org/10.1093/eurjpc/zwae110

Chicago

Szarek, Michael, Esther Reijnders, Ph Gabriel Steg, J Wouter Jukema, Markus Schwertfeger, Deepak L Bhatt, Vera A Bittner, et al. 2024. “Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.” European Journal of Preventive Cardiology 31 (10): e75–78. doi:10.1093/eurjpc/zwae110.